Q2 FY2026 EarningsQ2 FY26 missed consensus across key profitability and cash flow metrics despite having zero revenue in line with expectations. Net loss (GAAP) of -$52.8M was significantly wider than the -$41.2M consensus, while GAAP EPS of -$1.74 missed the -$0.99 mean estimate by 75.72%. Cash used in operations for the first half of FY26 totaled -$75.5M, tracking worse than the annualized consensus expectation, primarily driven by R&D scaling for OD-001 and a non-cash $8.7M contingent consideration charge following the May 2026 IPO.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Odyssey Therapeutics(ODTX) the EBIT is -55.47 M (--%), Miss estimate;the EPS is -1.74 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.06B--
-0.04B--
-0.01B--%
EPSMiss expectations
-1.74--
-0.9902--
-0.7498--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf